NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2002 (Second Quarter of Fiscal 2003)
Business Overview: The Company manufactures and distributes dietary supplements, vitamins, and minerals. Operations include contract manufacturing and a direct-to-consumer (DTC) product line marketed through television and other media channels. The Company operates primarily in the United States with a subsidiary in Switzerland (NAIE).

Key Financial Metrics

Note: All dollar amounts in thousands except per share data. Working Capital calculated as Current Assets ($17,084) minus Current Liabilities ($5,666). Total Debt includes Current portion of long-term debt ($567) and Long-term debt ($2,672).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 3% in the quarter and 16% for the six-month period compared to the prior year. Growth was driven by a 40% increase in DTC sales (quarterly) and a 12% increase in contract manufacturing sales (six-month).
• Profitability Turnaround: The Company returned to profitability, recording operating income of $658,000 for the six months ended Dec 31, 2002, compared to an operating loss of $185,000 in the same period in 2001.
• Margin Expansion: Gross profit margin improved to 23.9% (six months) from 21.0% (prior year), attributed to fixed cost leverage and lower material costs as a percentage of sales.
• Liquidity Improvement: Cash and cash equivalents rose from $640,000 at June 30, 2002, to $4,037,000 at December 31, 2002. This was driven by strong operating cash flow ($1.1 million) and a new credit facility.
• One-Time Income: The six-month period included a $225,000 settlement from the Vitamin Antitrust Litigation, which contributed to the net income.

Guidance, Outlook, Risks, and Contingencies

Management Commentary and Outlook

Management expects operating results to fluctuate due to the timing of revenue recognition and expenses. The Company believes its current cash and credit facilities are sufficient for near-term operations. Future funding depends on continued profitability, financing maintenance, and the success of its diversified growth strategy, including European expansion.

Key Risks

• Customer Concentration: Two customers accounted for 69% of net sales for the six months ended Dec 31, 2002. Loss of either would have a material adverse impact.
• Supplier Concentration: Two suppliers accounted for 43% of raw material purchases. Disruption could materially affect operations.
• Key Personality: The DTC product line (19% of sales) relies heavily on a key personality for marketing; loss of this relationship poses a risk.
• Regulatory Environment: Products are subject to FDA and FTC regulations. Changes in labeling or manufacturing regulations could require product reformulation or recalls.
• Competition: The market is highly competitive with larger manufacturers; price wars could adversely affect margins.

Contingencies

The Vitamin Antitrust Litigation was settled with a final payment of $225,000 received in the period. Management believes other ongoing legal actions will not have a material adverse effect.

Investor Verification Checklist

• Customer Dependency: Verify the stability of the two major customers representing 69% of sales.
• Debt Covenants: Review the terms of the new $6.5 million credit facility (effective Oct 31, 2002) to ensure compliance with covenants is maintained.
• Antitrust Proceeds: Note that the $225,000 litigation settlement is a non-recurring item and exclude it when assessing core operating profitability.
• Inventory Valuation: Monitor inventory levels ($7.3 million) and potential reserves given the reliance on specific raw material suppliers.
• DTC Growth Sustainability: Assess whether the 40% growth in direct-to-consumer sales is sustainable without the specific key personality mentioned in risk factors.